Keros Therapeutics (KROS) Shares Outstanding (Weighted Average) (2019 - 2025)

Keros Therapeutics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $37.2 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 0.58% year-over-year to $37.2 million; the trailing twelve-month figure through Dec 2025 stood at $37.2 million (down 0.58% YoY), and the FY2025 full-year result was $37.2 million, down 0.58% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $37.2 million, down from $40.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $40.6 million in Q3 2025, with the low at $23.2 million in Q1 2021.
• Historically, Shares Outstanding (Weighted Average) has averaged $30.7 million across 5 years, with a median of $29.5 million in 2023.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Weighted Average) soared 835.16% — and 2025, when it retreated 0.58%.
• Keros Therapeutics' Shares Outstanding (Weighted Average) stood at $23.3 million in 2021, then gained by 8.17% to $25.2 million in 2022, then increased by 16.66% to $29.4 million in 2023, then climbed by 27.14% to $37.4 million in 2024, then dropped by 0.58% to $37.2 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $37.2 million (Q4 2025), $40.6 million (Q3 2025), and $40.6 million (Q2 2025), per Business Quant data.